9th Annual Biomarkers Congress

Pharmacology: Harvard University

Total Score People Score Events Score
68 60 10
Date Event Presentation Speakers
October 17, 2013 14th Annual G Protein-Coupled Receptor (GPCR) Retreat Noncanonical GPCR signaling mechanisms Jean-Pierre Vilardaga
April 6, 2013 AACR Annual Meetings EPIGENETIC TARGETS FOR CANCER Anjana Rao, James E. Bradner
Developmental Origins of Cancer Chairperson: Richard J. Gilbertson, St. Jude Children's Research Hospital, Memphis, TN Stuart H. Orkin
Blood-Based Molecular Analysis of Cancer Daniel A Haber
Intrinsic and Microenvironment-Dependent Adaptive Responses that Regulate Drug Resistance Chairperson: Joan S. Brugge, Harvard Medical School, Boston, MA Joan S Brugge
The Interface Between Development and Cancer Using Model Organisms Chairperson: Michael M. Shen, Columbia University, New York, NY Leonard I. Zon
Emerging Single Cell Technologies in Cancer Research Chairperson: Garry P. Nolan, Stanford University School of Medicine, Stanford, CA Claude Lechene
Mutations in Epigenetic Regulators in Cancer Chairperson: Scott A. Armstrong, Memorial Sloan-Kettering Cancer Center, New York, NY Scott A. Armstrong
Mitotic Checkpoints Driving Cancer Therapeutic Strategies Chairperson: Peter K. Jackson, Genentech, Inc., South San Francisco, CA Timothy J Mitchison
Translational Control and Stress Response Pathways in Cancer Chairperson: Davide Ruggero, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA Karen Cichowski
Developmental and Molecular Origins of Brain Tumors Co-Chairpersons: Suzanne J. Baker, St. Jude Children's Research Hospital, Memphis, TN, and Cameron W. Brennan, Memorial Sloan-Kettering Cancer Center, New York, NY Cameron W Brennan
Synthetic Lethality and Genetic Approaches to Cancer Chairperson: Stephen J. Elledge, Harvard Medical School, Boston, MA Stephen J Elledge
Structural Aberrations in a Thousand Tumors Chairperson: Raju Kucherlapati, Harvard Medical School, Boston, MA Raju Kucherlapati
The Stanley J. Korsmeyer Memorial Symposium: Targeting Cell Death Pathways for Cancer Therapy Chairperson: Anthony G. Letai, Dana-Farber Cancer Institute, Boston, MA Anthony G. Letai
The Origins and Clinical Implications of Precancerous Lesions Chairperson: Cory Abate-Shen, Columbia University Irving Comprehensive Cancer Center, New York, NY Kornelia Polyak
Noncoding RNAs and Cancer Chairperson: Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA Jeannie T. Lee
New Cancer Vaccines Chairperson: Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA Glenn Dranoff
The Origins and Neoplastic Progression of Barrett's Esophagus Co-Chairpersons: Timothy C. Wang, Columbia University Medical Center, New York, NY, and Brian J. Reid, Fred Hutchinson Cancer Research Center, Seattle, WA Frank McKeon
Molecular Basis and Therapeutic Targeting of Bone Metastasis Co-Chairpersons: Yibin Kang, Princeton University, Princeton, NJ, and Matthew R. Smith, Massachusetts General Hospital Cancer Center, Boston, MA Matthew Smith
Molecular and Cellular Determinants of Brain Metastasis Co-Chairpersons: William C. Hahn, Dana-Farber Cancer Institute, Boston, MA, and Joan Massagué, Memorial Sloan-Kettering Cancer Center, New York, NY Rakesh K Jain, William C Hahn
Avatar: Individualized Human Cancer Models in Mice Kwok-Kin Wong
Next-Generation Therapeutic Modeling in Mice Pier Paolo
The Utility of Cancer Cell Line Screens for Modeling Drug Sensitivities Moderator: Jeffrey Settleman, Genentech, Inc., South San Francisco, CA Levi A Garraway
Clinical Trials Based on Mutations versus Histology William R Sellers, Lewis C Cantley
Human Papillomavirus: Beyond Cervical Cancer Chairperson: Maura L. Gillison, The Ohio State University Comprehensive Cancer Center, Columbus, OH Peter M Howley
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 1: Targeting Mechanisms of Therapeutic Resistance Chairperson: Matt V. Lorenzi, Janssen Research & Development, Spring House, PA Kwok-Kin Wong
Credentialing Response Biomarkers for Signal Transduction Inhibitors Chairperson: Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY Anthony G. Letai
Therapeutic Nanotechnology Chairperson: Gregory Lanza, Washington University, St. Louis, MO Omid C Farokhzad
Rational Combination Therapies in Cancer Chairperson: Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX Scott A. Armstrong
The Next Frontier in Targeted Therapy for Melanoma Chairperson to be announced Lynda Chin
New Paradigms in Molecular Pharmacology Chairperson: Angela N. Koehler, Broad Institute of MIT and Harvard, Cambridge, MA James E. Bradner
Metabolism and Signaling in Cancer Chairperson: Eyal Gottlieb, The Beatson Institute for Cancer Research, Glasgow, United Kingdom Nika N. Danial
Immune Modulation in the Tumor Microenviroment Chairperson: James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY Raghu Kalluri
Cancer Imaging in Mice and Men Andrew L. Kung, Dana-Farber Cancer Institute, Boston, MA Andrew Kung
2-Oxoglutarate-Dependent Dioxygenases as Targets of Cancer-Causing Mutations and Cancer Therapeutics William G. Kaelin, Jr., Dana-Farber Cancer Institute, Boston, MA William G Kaelin
Tumor-Secreted Factors Chairperson: David C. Lyden, Weill Cornell Medical College of Cornell University, New York, NY Xandra O Breakefield
Autocrine Activation of MET and Strategies to Overcome Adaptation for the Targeted Therapy of Acute Myeloid Leukemia A. Thomas Look, Dana-Farber Cancer Institute, Boston, MA Thomas A. Look
Stapled Peptides as Next-Generation Therapeutics Gregory L. Verdine, Harvard University, Cambridge, MA Gregory L Verdine
Prognostic and Predictive Biomarkers of Triple-Negative Breast Cancer Andrea L. Richardson, Brigham and Women's Hospital, Boston, MA Andrea L Richardson
Cancer Omics Beyond the Genome Sunney Xie
16th Annual Grant Writing Workshop Building Presence and Leadership through Empowered Communication Co-Chairpersons: Martine J. Piccart, Institut Jules Bordet, Brussels, Belgium, and Victoria M. Richon. Epizyme, Inc., Wellesley Hills, MA Kornelia Polyak
Patient-Derived Xenograft Models of Cancer: Where Are We Going? Chairperson: Matthew J. Ellis, Washington University Siteman Cancer Center, St. Louis, MO Tan Ince
WICR Career Mentoring Session Joan S Brugge
February 24, 2011 Targeting P13K / mTOR Signaling in Cancer Keynote Session Lewis C Cantley
Strategies for targeting the PI3K pathway when employing combination therapies Jeffrey Adam Engelman
The TSC-mTOR pathway regulates tumor cell metabolism downstream of PI3K Brendan Manning
PI3-Kinase and cancer cell metabolism Lewis C Cantley
Session 1 | PI3K/mTOR Signaling Lewis C Cantley
Targeting PI3K isoforms in cancer Jean J Zhao
Session 5 | Late-Breaking Research / Hot Topics Lewis C Cantley
February 13, 2011 Inositide Signaling in Pharmacology and Disease (X1) Keynote Session (Joint) | The Role of Phosphoinositides in Human Disease Lewis C Cantley
PI 3-Kinases (X2) | PI3K Pathway in Tumor Cell Metabolism and Matrix Control Joan S Brugge
PI 3-Kinases (X2) | mTOR Controls Cellular Metabolism Downstream of PI3K Brendan Manning
PI 3-Kinases (X2) | Optimizing PI3K Targeting in Cancer, Mechanistic Insights Jeffrey Adam Engelman
April 6, 2010 IBCs 5th Annual China 2010 Pharmaceutical R&D Summit China's Healthcare Reform: Implications for the Industrial Sectors Yuan-Li Liu
August 5, 2009 New Frontiers in Cancer Drug Development A New Paradigm for Translational Cancer Research: Targeting Endocrine Factors and Real Human Tumors Sandra S. McAllister
Turning Cancer Sequencing Data into Therapeutic Targets Heidi Greulich
Combinations of Novel and Conventional Cancer Agents: Challenges and Opportunities Kenneth C Anderson
The Use of Genetically Engineered Mouse Lung Cancer Models to Assess Effectiveness of Targeted Therapeutic Combinations Kwok-Kin Wong
The Evolving Treatment Paradigm in Multiple Myeloma Kenneth C Anderson
October 12, 2008 15th North American Regional Meeting - International Society for the Study of Xenobiotics Resolvins and Protectins : Anti-inflammatory and Pro-resolving Actions of Omega-3 Fatty Acid-derived Mediators Matthew Spite
June 18, 2008 Accelerating Anticancer Agent Development and Validation Workshop Proof of Concept to Pre-Clinical Scientist George Daniel Demetri
May 30, 2008 ASCO Annual'08 Meeting breast cancer-- Adjuvant Chemotherapy of Breast Cancer: Do We Still Need Anthracyclines? Eric P. Winer
breast cancer-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14A) Judy E Garber
breast cancer-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14B) Judy E Garber
cancer genetics-- Molecular Pathways of Cancer Predisposition in Children, Adolescents, and Young Adults Lisa Diller
cancer genetics-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14A) Judy E Garber
cancer genetics-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14B) Judy E Garber
cancer prevention/epidemiology-- Molecular Pathways of Cancer Predisposition in Children, Adolescents, and Young Adults Lisa Diller
cancer prevention/epidemiology-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14A) Judy E Garber
cancer prevention/epidemiology-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14B) Judy E Garber
central nervous system tumors-- Managing the Medical Complications of Patients with Brain Tumors (CPO10A) Patrick Y. Wen
central nervous system tumors-- Managing the Medical Complications of Patients with Brain Tumors (CPO10B) Patrick Y. Wen
clinical trials-- Early Data: Presenting and Publishing Preliminary Results Donna S. Neuberg
ethics-- Early Data: Presenting and Publishing Preliminary Results Donna S. Neuberg
gastrointestinal (noncolorectal) cancer-- Gastrointestinal Stromal Tumor (GIST) Comes of Age: Current Management Using Molecular Pathology, Surgery, and Targeted Therapy George Daniel Demetri
geriatric oncology--Adjuvant Chemotherapy of Breast Cancer: Do We Still Need Anthracyclines? Eric P. Winer
lung cancer-- Targeted and Novel Agents in Small Cell Lung Cancer Bruce E. Johnson
melanoma/skin cancers-- Melanoma in Children, Adolescents, and Young Adults David E Fisher
patient and survivor care-- Managing the Medical Complications of Patients with Brain Tumors (CPO10A) Patrick Y. Wen
patient and survivor care-- New Models for Survivorship Care Programs (M15) Lawrence N. Shulman
patient and survivor care-- Treatment Approaches and Functional Outcomes in Pediatric Sarcomas Mark Gebhardt
patient and survivor care-- Managing the Medical Complications of Patients with Brain Tumors (CPO10B) Patrick Y. Wen
pediatric cancer-- Molecular Pathways of Cancer Predisposition in Children, Adolescents, and Young Adults Lisa Diller
pediatric cancer-- Challenges and Optimizing Outcomes in Adolescents and Young Adults with Cancer Karen H. Albritton
pediatric cancer-- Treatment Approaches and Functional Outcomes in Pediatric Sarcomas Mark Gebhardt
pediatric cancer-- Melanoma in Children, Adolescents, and Young Adults David E Fisher
sarcoma/bone and soft tissue cancers-- Predicting and Targeting Drug Resistance to Tyrosine Kinase Inhibitors Jeffrey Adam Engelman
sarcoma/bone and soft tissue cancers-- Treatment Approaches and Functional Outcomes in Pediatric Sarcomas Mark Gebhardt
tumor biology-- Predicting and Targeting Drug Resistance to Tyrosine Kinase Inhibitors Jeffrey Adam Engelman
meet the professor sessions-- New Models for Survivorship Care Programs (M15) Lawrence N. Shulman
clinical problems in oncology-- Managing the Medical Complications of Patients with Brain Tumors (CPO10A) Patrick Y. Wen
clinical problems in oncology-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14A) Judy E Garber
clinical problems in oncology-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14B) Judy E Garber
clinical problems in oncology-- Managing the Medical Complications of Patients with Brain Tumors (CPO10B) Patrick Y. Wen
May 1, 2008 Engineering Protein Therapeutics for Delivery Engineering Human Anti-Viral Monoclonal Antibodies to Have Broad Neutralization Activity Against Multiple Variant Strains Wayne A Marasco
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.